Clinical Trials in Manchester, UK, page 7 of 7

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Active, closed

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850Immunoglobulin A Nephropathy

Travere Therapeutics, Inc.

Phase 3

406

Reading, Cambridge, Middlesbrough, Derby, Brighton, London, Manchester, Salford

2018-12-11

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

Advanced Accelerator Applications

Observational

1,014

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield

2018-11-28

Active, closed

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

NCT03802799Fragile X Syndrome

Zynerba Pharmaceuticals, Inc.

Phase 2/3

476

Leicester, Edinburgh, Manchester

2018-11-09

Active, closed

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299Hemophilia A

Bayer

Phase 1/2

Manchester

2018-11-07

Active, closed

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Phase 3

895

Guildford, Manchester, Sheffield, Southampton, Swansea

2018-10-31

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

AbbVie

Phase 3

265

Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth

2018-10-22

Active, closed

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

NCT03616587ER+ HER2- Advanced Breast Cancer

AstraZeneca

Phase 1

396

Cambridge, Leeds, London, Manchester, Sutton

2018-10-11

Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933Ewing Sarcoma, Colorectal Adenocarcinoma

Inhibrx Biosciences, Inc

Phase 1

411

London, Manchester

2018-10-08

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

Exelixis

Phase 3

187

Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester

2018-10-05

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

AstraZeneca

Phase 3

730

Manchester, Truro

2018-09-27

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

Merck Sharp & Dohme LLC

Phase 3

976

Cambridge, London, Sutton, Manchester

2018-09-12

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

Merck Sharp & Dohme LLC

Phase 3

3,500

Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston

2018-08-21

Active, closed

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076Carcinoma, Non-Small-Cell Lung

Hoffmann-La Roche

Phase 3

257

London, Manchester

2018-08-16

Active, closed

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110Breast Cancer

Daiichi Sankyo

Phase 3

524

Exeter, Aberdeen, London, Manchester, Edinburgh, Nottingham, Guildford

2018-08-09

By invitation

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric

Autolus Limited

Phase 2

500

Glasgow, London, Manchester, Newcastle upon Tyne

2018-08-02

Active, closed

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL

Genmab

Phase 1/2

666

Manchester, Plymouth, Southampton, Sutton

2018-06-26

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Global Development, Inc.

Phase 3

565

Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester

2018-06-21

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791Hepatocellular Carcinoma

Exelixis

Phase 3

837

Bristol, Cambridge, London, Manchester, Belfast

2018-06-10

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer

Regeneron Pharmaceuticals

Phase 1/2

890

Oxford, Sutton, London, Manchester

2018-05-21

Active, closed

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458Hepatocellular Carcinoma, Liver Cancer

Bristol-Myers Squibb

Phase 3

545

London, Manchester, Metropolitan Borough of Wirral

2018-04-18

By invitation

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

NCT03391778Neoplasms

USWM CT, LLC

Phase 1

250

London, Manchester, Sutton

2018-04-09

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

AbbVie

Phase 3

1,336

Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford

2018-04-09

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

Janssen Research & Development, LLC

Phase 3

629

Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton

2018-03-23

Active, closed

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT03436485Prostate Cancer Metastatic

Orion Corporation, Orion Pharma

Phase 1/2

204

Bedlington, Cardiff, Glasgow, Liverpool, London, Manchester, Preston

2018-03-19

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

AstraZeneca

Phase 2

273

Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester

2018-03-07

Active, closed

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

NCT02922036Heart Failure

EBR Systems, Inc.

Not applicable

300

Liverpool, London, Manchester, Middlesbrough, Oxford

2018-01-17

Active, closed

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940Small Cell Lung Carcinoma

Amgen

Phase 1

269

Manchester

2017-12-26

Active, closed

Endurant CHevAr New Indication Trial: ENCHANT

NCT03320252AAA - Abdominal Aortic Aneurysm

Medtronic Cardiovascular

Observational

150

London, Manchester

2017-10-26

Active, closed

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

NCT03019406Glycogen Storage Disease Type II-Pompe's Disease

Genzyme, a Sanofi Company

Phase 2

London, Manchester

2017-10-12

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer

Apollomics Inc.

Phase 2

497

London, Manchester, Surrey Quays

2017-09-27

Active, closed

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418Cancer

Hoffmann-La Roche

Phase 3

382

London, Manchester, Metropolitan Borough of Wirral, Nottingham, Surrey

2017-09-20

Active, closed

Personalized Therapy Study - Attain Stability Quad Post-Approval Study

NCT04024943Heart Failure

Medtronic

Observational

1,092

Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield

2017-08-21

Active, closed

Study of E7386 in Participants With Selected Advanced Neoplasms

NCT03264664Advanced Neoplasms

Eisai Inc.

Phase 1

Glasgow, Manchester, Sutton, London

2017-07-27

Active, closed

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616Non Small Cell Lung Cancer NSCLC

AstraZeneca

Phase 3

1,186

Leicester, London, Manchester

2017-06-01

Active, closed

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease

Pharmacyclics Switzerland GmbH

Phase 4

297

Cardiff, Leeds, London, Manchester

2017-05-22

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

Pfizer

Phase 3

296

Ipswich, Birmingham, Manchester

2017-04-27

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1/2

500

London, Manchester, Sutton

2017-03-07

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 3

310

Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton

2017-02-02

Active, closed

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

NCT03049189Neuroendocrine Tumors

ITM Solucin GmbH

Phase 3

324

London, Manchester

2017-02-02

Active, closed

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661Muscle Invasive Bladder Cancer

AstraZeneca

Phase 1

117

Glasgow, London, Manchester, Southampton

2016-12-28

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 2

900

Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester

2016-12-22

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906Neoplasms

Janssen Research & Development, LLC

Phase 1/2

234

Glasgow, London, Manchester, Newcastle upon Tyne

2016-11-21

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

Eisai Inc.

Phase 3

1,069

Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester

2016-10-13

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

Janssen Research & Development, LLC

Phase 1

751

Manchester, Newcastle upon Tyne, Sutton

2016-05-24

Active, closed

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

Eli Lilly and Company

Phase 2

309

London, Manchester, Acton, Bebbington, Sutton

2016-05-19

Active, closed

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004Ovarian, Breast, SCLC, Gastric Cancers

AstraZeneca

Phase 1/2

264

Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton

2016-03-17

Active, closed

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611Chronic Lymphocytic Leukemia

Acerta Pharma BV

Phase 2

Bournemouth, Leeds, Manchester

2016-03-08

Active, closed

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284Neoplasms

Tesaro, Inc.

Phase 1

729

Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton

2016-03-07

Active, closed

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms

Hoffmann-La Roche

Phase 2

534

Cambridge, London, Manchester

2015-11-19

Active, closed

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293Non Small Cell Lung Carcinoma NSCLC

AstraZeneca

Phase 3

953

Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton

2015-11-03

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

AstraZeneca

Phase 3

1,126

Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield

2015-11-02

Active, closed

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454Atopic Dermatitis

Regeneron Pharmaceuticals

Phase 3

880

London, Manchester, Sheffield

2015-10-15

Active, closed

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423Solid Tumors, Lymphoma

Taiho Oncology, Inc.

Phase 1/2

253

Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester

2015-07-14

Active, closed

Micra Transcatheter Pacing System Post-Approval Registry

NCT02536118Bradycardia

Medtronic

Observational

3,100

Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough

2015-07

Active, closed

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736Prostatic Neoplasms

Aragon Pharmaceuticals, Inc.

Phase 3

982

Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral

2014-11-26

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

Eli Lilly and Company

Phase 3

493

Bebbington, Cambridge, Manchester, Sutton

2014-11-06

Active, closed

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

AstraZeneca

Phase 1

358

Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington

2014-10-31

Active, closed

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NCT01872260Breast Cancer

Novartis Pharmaceuticals

Phase 1/2

259

Glasgow, Manchester

2013-10-22

Active, closed

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

AstraZeneca

Phase 3

510

Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton

2013-09-25

Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Janssen Research & Development, LLC

Phase 3

700

Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2013-09-09

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

AstraZeneca

Phase 3

327

Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton

2013-09-03

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2

Alexion Pharmaceuticals, Inc.

Observational

300

Cambridge, London, Manchester, Salford, Birmingham

2013-05-30

Active, closed

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma

MedImmune LLC

Phase 2

571

Leeds, Leicester, London, Maidstone, Manchester, Metropolitan Borough of Wirral, Plymouth, Southampton

2013-05-17

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183Atypical Hemolytic-Uremic Syndrome

Alexion Pharmaceuticals, Inc.

Observational

3,000

Cardiff, Exeter, London, Manchester, Newcastle, Southampton, Wales

2013-03-18

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110IGF1 Deficiency

Esteve Pharmaceuticals, S.A.

Observational

500

Belfast, Birmingham, Leeds, London, Manchester

2008-12-09

Active, closed

Phase I Comparative Bioavailability Study

NCT00777582Solid Tumors

AstraZeneca

Phase 1

197

Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton

2008-10-27

Active, closed

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

NCT00781612Neoplasm Metastasis

Genentech, Inc.

Phase 2

378

Dundee, Edinburgh, Grimsby, Lancaster, London, Manchester, Middlesex, Nottingham

2008-10-16

Recruiting

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy

Exactech

Observational

20,000

Reading, Yeovil, Bath, Bedford, Ipswich, Leicester, Manchester, Nottingham

2007-07-19

Recruiting

Pompe Disease Registry Protocol

NCT00231400Glycogen Storage Disease Type II, Pompe Disease

Genzyme, a Sanofi Company

Observational

2,000

Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne

2004-09-15

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

Cambridge, Birmingham, London, Salford, Belfast, Manchester

2001-07-31

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

Cambridge, Birmingham, London, Salford, Manchester

1991-04-01

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester?page=7

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →